Immunology specialist Khartis Therapeutics emerges from stealth with $95m
Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of…
14 Aug 2026
BMS secures FDA accelerated approval for Zenbexus in multiple myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple…
14 Aug 2026
Xanadu and University of Alberta to develop quantum algorithms for cancer
Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to treat cancer. The collaboration aims to develop new quantum algorithms…
13 Aug 2026
United global response to US childhood vaccine overhaul
International health authorities have launched a staunch defence of childhood immunisation, following a recent upheaval in the US that could significantly curb vaccine recommendations for the age group. As per…
13 Aug 2026
Akeso secures China NMPA authorisation for ivonescimab combo
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small…
13 Aug 2026
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits
Eli Lilly has initiated a crackdown to curb the trade of illicit forms of its investigational weight loss therapy, retatrutide, as around one in five patients turn to non-vetted sellers…
13 Aug 2026
Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s…